A5078793148- Acute Myeloid Leukemia Research
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Histone Deacetylase Inhibitors Research
- Economic and Financial Impacts of Cancer
- Vector-Borne Animal Diseases
- Hematopoietic Stem Cell Transplantation
- CNS Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Animal Disease Management and Epidemiology
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Hematological disorders and diagnostics
- Neutropenia and Cancer Infections
- Cancer therapeutics and mechanisms
- Biosimilars and Bioanalytical Methods
- Synthetic Organic Chemistry Methods
- Retinoids in leukemia and cellular processes
Albert Einstein College of Medicine
2013-2025
Montefiore Medical Center
2013-2025
The Bronx Defenders
2020-2024
Montefiore Einstein Comprehensive Cancer Center
2022-2024
All India Institute of Medical Sciences
2023
Sidney Kimmel Comprehensive Cancer Center
2023
Johns Hopkins University
2023
The University of Texas MD Anderson Cancer Center
2023
DR. B.R.A. Institute Rotary Cancer Hospital
2023
Johnson University
2018-2022
Abstract Patients with cancer are presumed to be at increased risk from COVID-19 infection–related fatality due underlying malignancy, treatment-related immunosuppression, or comorbidities. A total of 218 COVID-19–positive patients March 18, 2020, April 8, a malignant diagnosis were identified. 61 (28%) died case rate (CFR) 37% (20/54) for hematologic malignancies and 25% (41/164) solid malignancies. Six 11 (55%) lung disease. Increased mortality was significantly associated older age,...
Abstract Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center Bronx. Eight (80%) had received ≥ 3 lines therapy, six prior radiation, and seven recurrent disease after autologous hematopoietic stem transplant (AHCT). Our cohort included one patient HIV, two hepatitis B, CNS involvement Axi-cel led to...
In Brief OBJECTIVE: Obesity is an established risk factor for development of endometrial cancer. We hypothesized that obesity might also be associated with earlier age at cancer diagnosis, because mechanisms drive the obesity–endometrial association accelerate tumorigenesis. METHODS: A retrospective chart review was conducted all cases diagnosed from 1999 to 2009 a large medical center in New York City. The body mass index (BMI) comorbidities, stage, grade, and radiation treatment examined...
Abstract The novel coronavirus SARS-CoV2 has been observed to cause a higher incidence and greater severity of disease in males, as seen multiple cohorts across the globe. reasons for gender disparity is unclear can be due host factors. To determine whether males have delayed viral clearance after infection, we evaluated time symptomatic patients tested by serial oropharyngeal/nasopharyngeal swabs followed RT-PCR at reference lab Mumbai, India. A total 68 subjects with median age 37 years...
While therapies targeting CD19 by antibodies, CAR-T cells and T cell engagers have improved the response rates in B-cell malignancies; emergence of resistant populations with low expression can lead to relapsed disease. We developed an vitro model adaptive resistance facilitated chronic exposure leukemia a CD19-immunotoxin. Single-cell (sc) RNAseq showed increase transcriptionally distinct CD19low cells. Mass cytometry demonstrated that CD22 was also decreased these ATAC-seq chromatin...
Not available.
Abstract Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit deplete DNA methyltransferase 1 (DNMT1). HMAs standard single-agent therapies for myelodysplastic syndromes acute myelogenous leukemias. Several attempts to improve outcomes by combining with investigational agents, excepting the BCL2-inhibitor venetoclax, have failed in randomized clinical trial (RCT) evaluations. We extract lessons from decades of trials thereby inform future work....
Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is new standard of care for elderly patients with acute myeloid leukemia (AML) and being evaluated in myelodysplastic syndrome (MDS). Current dosing HMA/VEN relies on suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose (LDDec) has demonstrated activity malignancies. To overcome severe myelosuppression often seen HMA/VEN, we a VEN LDDec and/or frail...
Inherited germline defects are implicated in up to 10% of human tumors, with particularly well-known roles breast and ovarian cancers that harbor
Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) promising results, but data remain scarce. In this single-center retrospective analysis of 100 patients with ATLL from north America (67 acute, 22 lymphomatous), 17 underwent allo-SCT 5 autologous SCT (ASCT), a median follow-up 65 months. Post-transplant 3-years relapse incidence (RI) non-relapse mortality (NRM) were 51% 37%, respectively, 3-year...
Adoptive immunotherapy using CD19-targeted Chimeric antigen receptor T cells (CAR-T) has revolutionized the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Data is limited on propensity infections and lymphohematopoietic reconstitution after Day 30 (D30) following CAR-T cell therapy. In this study, we evaluated prevalence nature infectious complications in an expanded cohort DLBCL patients treated with CD19 therapy its association dynamics leukocyte subpopulation...
Multiple myeloma (MM) is a plasma cell neoplasm, which accounts for 1-2% of cancers and approximately 17% hematological malignancies in the United States each year. Fifty percent patients with symptomatic MM have three or more primary care visits before being referred to specialist, greater than any other cancer. A delay diagnosis multiple has been shown negatively impact clinical course disease; longer diagnostic intervals experience shorter disease-free survival higher rates...
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that continues to have poor prognosis despite recent therapeutic advances. Venetoclax (Ven), a BCL2-inhibitor has shown high response rate in AML; however, relapse invariable due mitochondrial dysregulation includes upregulation of the antiapoptotic protein MCL1, central mechanism Ven resistance (Ven-res). We previously demonstrated transcription factor STAT3 upregulated AML hematopoietic stem and progenitor cells (HSPCs)...